That kind of care makes a difference." These stories are backed by measurable results
Trials of tirzepatide in obesity and type 2 diabetes have shown improvements in blood pressure, cholesterol, and HbA1c (a marker of blood sugar control) alongside weight loss, though the SURMOUNT-MMO data will be the clearest evidence on cardiovascular outcomes
Alpha-linolenic acid (ALA ) and docosahexaenoic acid (DHA) , polyunsaturated omega-3 fatty acids found in flaxseed oil and fish , also increase GLP-1 and lower blood sugar
Methods Search Strategy and Study Selection The Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist was inspected for the systematic review ( Tables S1, S2 , respectively
Table of Contents How Retatrutide May Affect Blood Pressure Evidence From Clinical Trials on Cardiovascular Outcomes Who Should Exercise Caution With This Treatment Monitoring Blood Pressure During Retatrutide Therapy Interactions With Antihypertensive Medicines Current MHRA and NICE Guidance on Use in the UK Scientific References Frequently Asked Questions How Retatrutide May Affect Blood Pressure Retatrutide has been associated with modest blood pressure reductions in Phase 2 trials, most likely driven by weight loss-mediated decreases in vascular resistance, with additional contributions from possible natriuretic and endothelial effects extrapolated from the GLP-1 drug class
These findings are particularly relevant to the study of neurodegenerative conditions
